Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: bigbuk who wrote (131597)	4/21/2004 2:13:59 PM
From: StocksDATsoar	Respond to of 150070

YUP, DUMP A.S.A.P U THINK SEC SCREWED UP? COMTEX) B: Biocurex Tells SEC, 'Let's Talk,' Stands By Its Press Releases B: Biocurex Tells SEC, 'Let's Talk,' Stands By Its Press Releases Following Susp Apr 19, 2004 (financialwire.net via COMTEX) -- (FinancialWire) Biocurex Inc. (OTCBB: BOCX; OTC: BOCX) may be temporarily suspended from trading but it doesn't seem suspended from talking or taking issue with the U.S. Securities and Exchange Commission charges. The company's shares were temporarily suspended due to "questions regarding the accuracy of assertions by Biocurex and others, in press releases and e-mails to investors concerning, among other things, (1) a study confirming the effectiveness of its primary product and (2) approval of its main product by the Food and Drug Administration." Biocurex said it has "notified the SEC that it is eager to answer any questions the SEC may have regarding these issues and is presently awaiting a response from the SEC on this matter," and that "Biocurex is not responsible for the unauthorized circulation of corporate material 'by others', nor any material that could be construed as misleading to investors or outright erroneous in its content." The company also said that the U.S. Food and Drug Administration has classified Biocurex's Histo-RECAF(TM) as a Class I device under Regulation Number 864.1850, Code HZJ owned by BioCurex (FDA number 9046509). Thus, the product is available as a "Staining test for AFP receptors (a.k.a. RECAF) in tissues" for sale to pathology laboratories across the USA, and that the company "firmly stands by the results announced in its April 5, 2004 press release and by its RECAF technology in general." Friday, Biocurex stated that Protokinetix announced preliminary results from a study carried out by the George Pompidou Hospital in France which was designed to validate the Company's Histo-RECAF(TM) version 2.0. This version uses a high affinity anti-RECAF antibody which improves the contrast between cancer cells and the surrounding non-malignant tissue. "The study was commissioned by Protokinetix Inc., which was granted a license by BioCurex to commercialize therapeutic anti-RECAF antibodies modified according to Protokinetix's Super-Antibody proprietary technology and the Perigene (Compiegne, France) catalytic antibody technology," a company press release noted. It quoted Dr. Jean-Marie Dupuis, a scientist involved with the Pompidou validation study, as describing the results obtained with BioCurex kits as 'very positive' and stating that "the labeling of the malignant cells is strong and clear with a nice delineation between malignant and normal cells." CEO Dr. Ricardo Moro stated: "We are very pleased with these very preliminary results, which validate our claims at a time in which our technology is under scrutiny. "The findings are very significant because the study is being carried out by an extremely reputable institution. The results are also important to us because the study uses our new anti-RECAF antibody which works significantly better than the former reagent in the kit. "We are looking forward to the final conclusions of this study. We expect that the Pompidou analysis will continue to confirm the positive results we have obtained in our own research facilities. Moreover, we are excited about the potential of combining the Super-Antibody and the Catalytic-Antibody technologies with our own RECAF(TM) technology. "BioCurex has pending patents for a number of cancer therapy applications using RECAF(TM). These applications cover conjugates between anti-RECAF antibodies with a variety of drugs, radio-isotopes and a cancer vaccine." He said that this second version of Histo-RECAF being tested by the Pompidou group has not been yet submitted to the FDA. For up-to-the-minute news, features and links click on financialwire.net FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on investrend.com The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: investrend.com URL: financialwire.net (C) 2004 financialwire.net, Inc. All rights reserved. -0- * end of story *